The Patent Finder

Cellact Pharma GmbH

Also on record
Records under this name other than the patents Cellact Pharma GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Showing 1 to 5 of 5 · Back to Cellact Pharma GmbH

PatentTitleStatus Expires Confidence
US 7,794,715Anti-TIRC7 antibodies in therapy of inflammatory diseases
Term ended
Term ended Aug 22, 2026 · From the USPTO record
Term endedTerm ended Aug 22, 2026From the USPTO record
US 9,096,654Peptides capable of modulating the function of TIRC7
Term ended
Term ended Aug 17, 2026 · From the USPTO record
Term endedTerm ended Aug 17, 2026From the USPTO record
US 9,889,147Analogues of Etoposide for the Treatment of Tumours
Lapsed on the fee record
Ended Feb 13, 2026 · High confidence
Lapsed on the fee recordEnded Feb 13, 2026High confidence
US 9,827,261Etoposide and Prodrugs Thereof for Use in Targeting Cancer Stem Cells
Lapsed on the fee record
Ended Nov 28, 2025 · High confidence
Lapsed on the fee recordEnded Nov 28, 2025High confidence
US 10,806,745Analogues of Etoposide for the Treatment of Tumours
Lapsed on the fee record
Ended Oct 20, 2024 · Medium confidence
Lapsed on the fee recordEnded Oct 20, 2024Medium confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited